A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation is a phase 3 interventional study registered as NCT07174908, led by InxMed (Shanghai), and recruiting on the registry. Official title: A Phase 3 Multicenter, Randomised, Controlled, and Open-Label Study of IN10018 in Combination With D-1553 Versus Standard Therapy for the Treatment of First Line Locally-advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation. Planned enrolment is 400 participants (estimated). The study started in 2025-09-10 and primary completion is expected in 2028-09. No results have been posted on ClinicalTrials.gov.